Responding to an FDA warning - Geographic variation in the use of rosiglitazone

New England Journal of Medicine

Volumn 363, Issue 22, 2010, Pages 2081-2084

  Shah, Nilay D ^a   Montori, Victor M ^a   Krumholz, Harlan M ^b,c   Tu, Karen ^d,e,f   Alexander, G Caleb ^g,h   Jackevicius, Cynthia A ^d,f,i  

^a MAYO CLINIC   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁱ WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

CLINICAL DECISION MAKING; DRUG EXPOSURE; DRUG FORMULARY; DRUG MARKETING; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY; UNITED STATES;

EID: 78649404322     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1011042     Document Type: Short Survey

References (5)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. [Erratum, N Engl J Med 2007;357:100.]
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203.
3. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:369-86.
4. Geographic variation in health care spending. Washington, DC: Congressional Budget Office, 2008. (http://www.cbo.gov/ftpdocs/89xx/doc8972/02- 15-GeogHealth.pdf.)
5. Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010;340:c1344.